.Pharmacolibrary.Drugs.N_NervousSystem.N02C_AntimigrainePreparations.N02CC05_Almotriptan.Almotriptan .Pharmacolibrary.Drugs.N_NervousSystem.N02C_AntimigrainePreparations.N02CC05_Almotriptan.Almotriptan| name: | Almotriptan |
| ATC code: | N02CC05 | route: | oral |
| n-compartments | 1 |
Almotriptan is a selective serotonin 5-HT1B/1D receptor agonist (triptan) used for the acute treatment of migraine attacks with or without aura in adults. It is approved and currently used in several countries for this indication.
Pharmacokinetic parameters reported for healthy adult volunteers, both male and female, following single oral administration of almotriptan.
Baldwin, JR, et al., & Carel, BJ (2004). A comparison of the pharmacokinetics and tolerability of the anti-migraine compound almotriptan in healthy adolescents and adults. Cephalalgia : an international journal of headache 24(4) 288–292. DOI:10.1111/j.1468-2982.2004.00673.x PUBMED:https://pubmed.ncbi.nlm.nih.gov/15030538
Eiland, LS, & Hunt, MO (2010). The use of triptans for pediatric migraines. Paediatric drugs 12(6) 379–389. DOI:10.2165/11532860-000000000-00000 PUBMED:https://pubmed.ncbi.nlm.nih.gov/21028917
Fraser, IP, et al., & Winner, P (2012). Pharmacokinetics and tolerability of rizatriptan in pediatric migraineurs in a randomized study. Headache 52(4) 625–635. DOI:10.1111/j.1526-4610.2011.02069.x PUBMED:https://pubmed.ncbi.nlm.nih.gov/22289113